Contract research firm Anthem Biosciences files for Rs 3,395 crore IPO
Dec 31, 2024 · Contract research company Anthem Biosciences has filed for a Rs 3,395 crore ($397 million) initial public offering, as per the Draft Red Herring Prospectus filing with BSE on December 31.
Indian CDMO Anthem Biosciences plans $397 million IPO
1 day ago · Anthem Biosciences files for a $397 million IPO amid India’s record-breaking year for public listings. The Bengaluru-based CDMO aims to leverage rising global demand and reduced reliance on Chinese suppliers, aligning with India’s growing prominence in the pharmaceutical outsourcing market.
Anthem Biosciences Files for Rs 3,395 crore IPO - Groww
Jan 1, 2025 · Explore Anthem Biosciences IPO details, a Bengaluru-based CRDMO offering services across NCEs, NBEs, and fermentation-based APIs. Learn about their business, financials, shareholders, and market potential as they launch a Rs. 3,395 crore offer for sale.
Anthem Biosciences Submits DRHP for ₹3,395 Crore IPO
6 days ago · The ₹3,395 crore IPO marks a significant milestone for Anthem BioScience, reflecting its evolution from a niche drug discovery firm to a major player in the CRDMO industry. The offering highlights the growing importance of Indian pharmaceutical companies in the global supply chain, particularly in advanced therapeutic areas.
Anthem Biosciences files DRHP for Rs 3,395 crore IPO
Dec 31, 2024 · Anthem Biosciences, a CRDMO, has filed for a Rs 3,395 crore IPO. The offer comprises an OFS by promoters and investors, including True North. Anthem Biosciences, the Bengaluru-based contract research, development and manufacturing organisation (CRDMO) on Tuesday said it has filed for a Rs 3,395 ...
Anthem Biosciences files draft papers with Sebi for ₹3,395-crore IPO
Dec 31, 2024 · Anthem Biosciences on Tuesday (December 31, 2024) filed preliminary papers with capital markets regulator Sebi to float a ₹3,395-crore initial public offering. The proposed initial public offer ...
Indian drugmaker Anthem Biosciences files for $397 mln IPO
Dec 31, 2024 · Indian contract drugmaker Anthem Biosciences filed for a 33.95-billion-rupee ($397 million) initial public offering, draft papers showed on Tuesday, at the fag end of what has been a red-hot...
Anthem Biosciences files DRHP for Rs 3,395 crore IPO
Dec 31, 2024 · Anthem Biosciences has filed the draft red herring prospectus (DRHP) with capital markets regulator, SEBI for an IPO. The IPO of the Bangalore based company comprises an offer for Sale (OFS) of equity shares aggregating up to Rs 3,395 crore by the selling shareholders. Ajay Bhardwaj (Chairman, MD & CEO), Ishaan Bhardwaj (Vice President), Ganesh Sambasivam (Executive Director), and K Ravindra ...
Anthem Biosciences files draft papers with Sebi for Rs 3,395-crore IPO
6 days ago · Business News » IPO News. Anthem Biosciences files draft papers with Sebi for Rs 3,395-crore IPO The IPO is entirely an OFS, the company will not receive any funds from the issue and the proceeds will go to the selling shareholder. View in App; Anthem is into innovation-driven and technology-focused CRDMO with fully integrated operations ...
Anthem Biosciences Considers $400 Million IPO in India
Jul 9, 2024 · Anthem Biosciences Pvt., a Bengaluru-based contract drug researcher and manufacturer, is considering an initial public offering in India that could raise about $400 million, according to...
- Some results have been removed